These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 7705494)

  • 121. An assessment of methods for routine local monitoring of vaccine efficacy, with particular reference to measles and pertussis.
    Clarkson JA; Fine PE
    Epidemiol Infect; 1987 Oct; 99(2):485-99. PubMed ID: 3678405
    [TBL] [Abstract][Full Text] [Related]  

  • 122. A descriptive profile and the immune status of some hospitalised patients with measles.
    Oh HM; Lateef F; Chew SK; Doraisingham S
    Ann Acad Med Singap; 1995 May; 24(3):373-5. PubMed ID: 7574417
    [TBL] [Abstract][Full Text] [Related]  

  • 123. Measles control in the United Kingdom.
    Pollock TM
    Rev Infect Dis; 1983; 5(3):574-6. PubMed ID: 6879017
    [TBL] [Abstract][Full Text] [Related]  

  • 124. Measles seroprevalence among Dutch travelling families.
    Doornekamp L; Comvalius AD; GeurtsvanKessel CH; Slobbe L; Scherbeijn SMJ; van Genderen PJJ; van Binnendijk RS; van Gorp ECM; de Swart RL; Goeijenbier M
    Travel Med Infect Dis; 2021; 44():102194. PubMed ID: 34728385
    [TBL] [Abstract][Full Text] [Related]  

  • 125. Control of measles in Czechoslovakia (CSSR).
    Sejda J
    Rev Infect Dis; 1983; 5(3):564-7. PubMed ID: 6879015
    [TBL] [Abstract][Full Text] [Related]  

  • 126. Measles immunity and immunization status in under-5-year-old children in New South Wales: a population-based study.
    Ferson MJ; Robertson PW; Donovan JW
    J Paediatr Child Health; 1998 Aug; 34(4):339-41. PubMed ID: 9727174
    [TBL] [Abstract][Full Text] [Related]  

  • 127. Vaccine safety versus vaccine efficacy in mass immunisation programmes.
    Nokes DJ; Anderson RM
    Lancet; 1991 Nov; 338(8778):1309-12. PubMed ID: 1682694
    [TBL] [Abstract][Full Text] [Related]  

  • 128. Age-structure and transient dynamics in epidemiological systems.
    Magpantay FMG; King AA; Rohani P
    J R Soc Interface; 2019 Jul; 16(156):20190151. PubMed ID: 31362625
    [TBL] [Abstract][Full Text] [Related]  

  • 129. Deciphering the relative weights of demographic transition and vaccination in the decrease of measles incidence in Italy.
    Merler S; Ajelli M
    Proc Biol Sci; 2014 Feb; 281(1777):20132676. PubMed ID: 24403333
    [TBL] [Abstract][Full Text] [Related]  

  • 130. Are vaccinated measles cases protected against severe disease?
    Bonneton M; Antona D; Danis K; Aït-Belghiti F; Levy-Bruhl D
    Vaccine; 2020 Jun; 38(29):4516-4519. PubMed ID: 32418790
    [TBL] [Abstract][Full Text] [Related]  

  • 131. Measles in vaccinated communities.
    Warin JF; Mayon-White RT
    Lancet; 1971 Nov; 2(7732):1034-5. PubMed ID: 4108088
    [No Abstract]   [Full Text] [Related]  

  • 132. A review of measles virus.
    Stalkup JR
    Dermatol Clin; 2002 Apr; 20(2):209-15, v. PubMed ID: 12120435
    [TBL] [Abstract][Full Text] [Related]  

  • 133. Multiple attractors in the response to a vaccination program.
    Aron JL
    Theor Popul Biol; 1990 Aug; 38(1):58-67. PubMed ID: 2399511
    [TBL] [Abstract][Full Text] [Related]  

  • 134. Predicting and preventing measles epidemics in New Zealand: application of a mathematical model.
    Roberts MG; Tobias MI
    Epidemiol Infect; 2000 Apr; 124(2):279-87. PubMed ID: 10813154
    [TBL] [Abstract][Full Text] [Related]  

  • 135. Computers and the effectiveness of the measles vaccination campaign in England and Wales.
    Bussey AL; Harris AS
    Community Med; 1979 Feb; 1(1):29-35. PubMed ID: 477290
    [No Abstract]   [Full Text] [Related]  

  • 136. The UK immunisation schedule: changes to vaccine policy and practice in 2013/14.
    Atchison CJ; Hassounah S
    JRSM Open; 2015 Apr; 6(4):2054270415577762. PubMed ID: 25973215
    [TBL] [Abstract][Full Text] [Related]  

  • 137. Clustering of susceptible individuals within households can drive measles outbreaks: an individual-based model exploration.
    Kuylen E; Willem L; Broeckhove J; Beutels P; Hens N
    Sci Rep; 2020 Nov; 10(1):19645. PubMed ID: 33184409
    [TBL] [Abstract][Full Text] [Related]  

  • 138. Modelling the relative benefits of using the measles vaccine outside cold chain for outbreak response.
    Azam JM; Saitta B; Bonner K; Ferrari MJ; Pulliam JRC
    Vaccine; 2021 Sep; 39(40):5845-5853. PubMed ID: 34481696
    [TBL] [Abstract][Full Text] [Related]  

  • 139. Oncolytic Measles Virotherapy and Opposition to Measles Vaccination.
    Russell SJ; Babovic-Vuksanovic D; Bexon A; Cattaneo R; Dingli D; Dispenzieri A; Deyle DR; Federspiel MJ; Fielding A; Galanis E; Lacy MQ; Leibovich BC; Liu MC; Muñoz-Alía M; Miest TC; Molina JR; Mueller S; Okuno SH; Packiriswamy N; Peikert T; Raffel C; Van Rhee F; Ungerechts G; Young PR; Zhou Y; Peng KW
    Mayo Clin Proc; 2019 Sep; 94(9):1834-1839. PubMed ID: 31235278
    [TBL] [Abstract][Full Text] [Related]  

  • 140. Immunisation and herd immunity.
    Anderson RM; May RM
    Lancet; 1990 Mar; 335(8690):641-5. PubMed ID: 1969023
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.